-
UK Group Invests in Keapstone Therapeutics for Parkinson’s Research
With its recent award of £1 million (about $1.3 million USD), Parkinson’s UK continues to invest in Keapstone Therapeutics, bringing the biotechnology company closer to developing treatments for Parkinson’s and motor neuron disease (MND), it was announced.
Keapstone officials also hope the funding, which will go toward specific preclinical packages, will attract further investment. Its focus is developing a disease-altering therapeutic approach to the diseases.
Are you familiar with Keapstone Therapeutics? Are you interested in learning more about the projects this money will fund?
Sorry, there were no replies found.
Log in to reply.